Skip to main content
Premium Trial:

Request an Annual Quote

Advion Acquires NanoTek; Plans to Offer Combined Microfluidics Platform for Biomarker Research

NEW YORK (GenomeWeb News) - Bioanalytical contract services provider Advion BioSciences this week said it has acquired microfluidic chemistry firm NanoTek for an undisclosed sum.
Advion said it plans to use NanoTek's technology in combination with its own micro- and nanoscale LC-MS analytical platform to offer chemistry and analytical services for biomarker research, drug discovery, and imaging diagnostics.
Prior to the acquisition, Advion was NanoTek’s global distribution and support partner.
David Patteson, CEO of the Ithaca, NY-based Advion, said the deal is “extremely strategic ... and accretive to earnings from day one.” He added, “We intend to rapidly accelerate the NanoTek global commercialization and extend the product lines into pre-existing demand areas.”
Advion said it will keep NanoTek CEO Joe Matteo on staff as president of Advion’s Accelerated Chemistry division, which is based in Knoxville, Tenn.

The Scan

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.

Tibetan Study Finds Adaptive Variant Influencing Skin Pigmentation

With a combination of phenotyping and genetic data, researchers document at PNAS a Tibetan-enriched enhancer variant influencing melanin synthesis and ultraviolet light response.

Domestication Linked to Nervous System Genes in Inbred Mouse Strains

Researchers highlighted more than 300 positively selected genes in domesticated mice, including genes linked to nervous system function or behavior in Genome Biology.

ALS Genetic Testing May Be Informative Across Age Ranges, Study Finds

Researchers in the journal Brain identified clinically actionable variants in a significant subset of older ALS patients, prompting them to point to the potential benefits of broader test use.